Universe Pharmaceuticals INC
UPC
$4.20
$0.4010.53%
NASDAQ
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -22.33% | -20.81% | -19.52% | -24.22% | -28.15% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -22.33% | -20.81% | -19.52% | -24.22% | -28.15% |
| Cost of Revenue | -4.84% | 7.20% | 20.50% | 7.91% | -3.14% |
| Gross Profit | -47.02% | -50.57% | -52.88% | -49.83% | -47.36% |
| SG&A Expenses | -28.69% | -46.77% | -58.82% | -36.26% | -3.63% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -63.51% | -34.68% | -7.13% | -25.23% | -37.14% |
| Total Operating Expenses | -27.61% | -26.10% | -24.69% | -9.61% | 7.81% |
| Operating Income | 45.79% | 48.69% | 52.59% | -1,751.22% | -248.93% |
| Income Before Tax | -49.93% | -7.23% | 51.78% | -2,585.82% | -248.52% |
| Income Tax Expenses | 1,248.86% | 379.25% | 207.50% | 8.07% | -90.26% |
| Earnings from Continuing Operations | -65.86% | -24.05% | 29.46% | -512.40% | -289.43% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.86% | -24.05% | 29.46% | -512.40% | -289.43% |
| EBIT | 45.79% | 48.69% | 52.59% | -1,751.22% | -248.93% |
| EBITDA | 48.20% | 51.61% | 56.29% | -4,278.09% | -231.75% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |